BNP Paribas Financial Markets
GALT icon

BNP Paribas Financial Markets’s Galectin Therapeutics GALT Stock Holding History

BNP Paribas Financial Markets’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.4K Sell
10,216
-1,600
-14% -$4.15K ﹤0.01% 4909
2026
Q1 		$33K Sell
11,816
-1,702
-13% -$5.18K ﹤0.01% 4905
2025
Q4 		$56.2K Buy
13,518
+13,381
+9,767% +$70.5K ﹤0.01% 4628
2025
Q3 		$580 Sell
137
-1,422
-91% -$5.35K ﹤0.01% 5299
2025
Q2 		$3.29K Hold
1,559
– – ﹤0.01% 5005
2025
Q1 		$1.9K Sell
1,559
-4,041
-72% -$5.67K ﹤0.01% 4988
2024
Q4 		$7.22K Buy
5,600
+145
+3% +$348 ﹤0.01% 4890
2024
Q3 		$15K Buy
5,455
+3,990
+272% +$9.8K ﹤0.01% 3774
2024
Q2 		$3.31K Buy
+1,465
New +$4.45K ﹤0.01% 3788
2022
Q4 		– Sell
-13
Closed -$21 – 4254
2022
Q3 		$21 Hold
13
– – ﹤0.01% 4691
2022
Q2 		$17 Hold
13
– – ﹤0.01% 4057
2022
Q1 		$21 Hold
13
– – ﹤0.01% 4121
2021
Q4 		$27 Sell
13
-629
-98% -$1.8K ﹤0.01% 4178
2021
Q3 		$2.49K Hold
642
– – ﹤0.01% 3772
2021
Q2 		$2.05K Sell
642
-4,643
-88% -$16.5K ﹤0.01% 3882
2021
Q1 		$11.5K Sell
5,285
-1,660
-24% -$3.72K ﹤0.01% 3819
2020
Q4 		$15.6K Sell
6,945
-1,484
-18% -$3.89K ﹤0.01% 3882
2020
Q3 		$22.5K Buy
8,429
+7,171
+570% +$20.1K ﹤0.01% 3791
2020
Q2 		$3.85K Sell
1,258
-11,202
-90% -$28.2K ﹤0.01% 4091
2020
Q1 		$24.4K Buy
12,460
+6,656
+115% +$16.2K ﹤0.01% 3851
2019
Q4 		$16.6K Buy
5,804
+1,705
+42% +$5.92K ﹤0.01% 4047
2019
Q3 		$15K Buy
4,099
+4,016
+4,839% +$14.5K ﹤0.01% 4060
2019
Q2 		$344 Buy
+83
New +$359 ﹤0.01% 4432
2015
Q2 		– Sell
-384
Closed -$1.29K – 3569
2015
Q1 		$1.29K Buy
+384
New +$1.37K ﹤0.01% 3536
2014
Q4 		– Sell
-897
Closed -$4.51K – 2449
2014
Q3 		$4.51K Buy
+897
New +$6.99K ﹤0.01% 3832

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BNP Paribas Financial Markets's GALT Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Galectin Therapeutics (GALT) stake by 14% in Q2 2026, selling an estimated $4.15K and leaving 10,216 shares worth $47.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4909.

BNP Paribas Financial Markets first reported a position in GALT in Q3 2014 and has held it in 25 quarters since. The position peaked at $56.2K in Q4 2025. 94 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • BNP Paribas Financial Markets held 10,216 shares of Galectin Therapeutics worth $47.4K as of Q2 2026.
  • BNP Paribas Financial Markets sold 1,600 Galectin Therapeutics shares in Q2 2026, an estimated $4.15K.
  • Galectin Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4909 holding.
  • BNP Paribas Financial Markets first reported a position in Galectin Therapeutics in Q3 2014 and has held it in 25 quarters since.
  • BNP Paribas Financial Markets's Galectin Therapeutics position peaked at $56.2K in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.